SI2580236T1 - Muteini lipokalina solz, ki vežejo IL-4 R alfa - Google Patents
Muteini lipokalina solz, ki vežejo IL-4 R alfaInfo
- Publication number
- SI2580236T1 SI2580236T1 SI201131711T SI201131711T SI2580236T1 SI 2580236 T1 SI2580236 T1 SI 2580236T1 SI 201131711 T SI201131711 T SI 201131711T SI 201131711 T SI201131711 T SI 201131711T SI 2580236 T1 SI2580236 T1 SI 2580236T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alpha
- tear lipocalin
- lipocalin muteins
- muteins binding
- binding
- Prior art date
Links
- 102000003752 Lipocalin 1 Human genes 0.000 title 1
- 108010057281 Lipocalin 1 Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35246110P | 2010-06-08 | 2010-06-08 | |
| EP11726380.6A EP2580236B1 (en) | 2010-06-08 | 2011-06-08 | Tear lipocalin muteins binding il-4 r alpha |
| PCT/EP2011/059420 WO2011154420A2 (en) | 2010-06-08 | 2011-06-08 | Tear lipocalin muteins binding il-4 r alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2580236T1 true SI2580236T1 (sl) | 2019-08-30 |
Family
ID=44627297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131711T SI2580236T1 (sl) | 2010-06-08 | 2011-06-08 | Muteini lipokalina solz, ki vežejo IL-4 R alfa |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8986951B2 (enExample) |
| EP (1) | EP2580236B1 (enExample) |
| JP (3) | JP5902679B2 (enExample) |
| CN (3) | CN103038249B (enExample) |
| AU (1) | AU2011263786B2 (enExample) |
| CA (1) | CA2800026C (enExample) |
| CY (1) | CY1122339T1 (enExample) |
| DK (1) | DK2580236T3 (enExample) |
| ES (1) | ES2729652T3 (enExample) |
| HR (1) | HRP20190689T1 (enExample) |
| HU (1) | HUE043835T2 (enExample) |
| LT (1) | LT2580236T (enExample) |
| NZ (1) | NZ603562A (enExample) |
| PL (1) | PL2580236T3 (enExample) |
| PT (1) | PT2580236T (enExample) |
| RS (1) | RS58839B1 (enExample) |
| RU (1) | RU2569745C2 (enExample) |
| SG (1) | SG186161A1 (enExample) |
| SI (1) | SI2580236T1 (enExample) |
| SM (1) | SMT201900297T1 (enExample) |
| TR (1) | TR201906295T4 (enExample) |
| WO (1) | WO2011154420A2 (enExample) |
| ZA (1) | ZA201209160B (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4976412B2 (ja) | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
| AU2011263786B2 (en) * | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| US9140696B2 (en) | 2011-11-16 | 2015-09-22 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| HRP20191771T1 (hr) | 2011-11-16 | 2019-12-27 | Adrenomed Ag | Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije |
| ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| BR112014011670B1 (pt) | 2011-11-16 | 2021-05-25 | Adrenomed Ag | anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica |
| PL3553084T3 (pl) | 2011-11-16 | 2023-04-17 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan |
| HRP20190122T1 (hr) | 2011-11-16 | 2019-03-08 | Adrenomed Ag | Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću |
| EP3453400B1 (en) | 2011-12-13 | 2021-01-20 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| ES2810001T3 (es) | 2012-10-02 | 2021-03-08 | Sphingotec Gmbh | Un método para diagnosticar o monitorizar la función renal |
| EP2920202B1 (en) * | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| RU2677895C2 (ru) | 2013-01-08 | 2019-01-22 | Сфинготек Гмбх | Уровни гормона роста натощак в качестве прогностического маркера сердечно-сосудистого риска |
| WO2014140210A1 (en) * | 2013-03-14 | 2014-09-18 | Pieris Ag | Novel binding proteins for pcsk9 |
| WO2014147153A1 (en) | 2013-03-20 | 2014-09-25 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
| EP3145945B1 (en) | 2014-05-22 | 2020-07-15 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
| WO2016113203A1 (en) * | 2015-01-12 | 2016-07-21 | Pieris Ag | Engineered t cells and uses therefor |
| ES3075629T3 (en) | 2015-04-24 | 2026-08-06 | Sphingotec Gmbh | A method for predicting the risk of incidence of chronic kidney disease |
| EP3298029A1 (en) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| TW201725212A (zh) * | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| IL262472B2 (en) | 2016-04-21 | 2024-12-01 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitors for use in treating diseases related to necrosis |
| US11390661B2 (en) | 2016-06-27 | 2022-07-19 | Aicuris Anti-Infective Cures Gmbh | HCMV entry inhibitors |
| CN109716136B (zh) | 2016-07-08 | 2023-09-22 | 斯弗因高泰克有限公司 | 肾上腺髓质素用于评估急性心力衰竭患者的充血 |
| EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| KR20190120174A (ko) | 2016-12-16 | 2019-10-23 | 아드레노메드 아게 | 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| RU2019144031A (ru) | 2017-05-30 | 2021-06-30 | Сфинготек Гмбх | Способ диагностики или мониторинга функции почек или диагностики дисфункции почек |
| US20220227854A1 (en) | 2017-09-25 | 2022-07-21 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
| MX2020004072A (es) | 2017-10-18 | 2020-07-28 | Adrenomed Ag | Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm). |
| RU2020115377A (ru) | 2017-10-24 | 2021-11-25 | Сфинготек Гмбх | Селенопротеин p для прогнозирования первого сердечно-сосудистого явления |
| KR102835427B1 (ko) | 2017-10-25 | 2025-07-21 | 4틴4 파마슈티컬스 게엠베하 | 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도 |
| KR102717599B1 (ko) | 2018-02-08 | 2024-10-14 | 스핑고텍 게엠베하 | 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제 |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| CA3124020A1 (en) | 2018-12-20 | 2020-06-25 | Sphingotec Gmbh | Selenoprotein p in heart failure |
| US20220211798A1 (en) | 2018-12-21 | 2022-07-07 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
| CN113939307A (zh) | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| EP3946415A1 (en) * | 2019-03-29 | 2022-02-09 | Astrazeneca AB | Lipocalin mutein for treatment of asthma |
| US20220291234A1 (en) | 2019-08-15 | 2022-09-15 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients |
| WO2021038078A1 (en) | 2019-08-30 | 2021-03-04 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| US11231198B2 (en) | 2019-09-05 | 2022-01-25 | Trane International Inc. | Systems and methods for refrigerant leak detection in a climate control system |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| CN115244401A (zh) | 2020-02-27 | 2022-10-25 | 4Teen4制药有限公司 | 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3 |
| CA3168978A1 (en) | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| CN115244081A (zh) | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗休克患者的抗肾上腺髓质素(adm)结合剂 |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| US20210285949A1 (en) | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| US20230213519A1 (en) | 2020-03-16 | 2023-07-06 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
| MX2023007174A (es) | 2020-12-18 | 2023-09-08 | Astrazeneca Ab | Formulacion de polvo seco de muteina de lipocalina para el tratamiento del asma. |
| US20240272178A1 (en) | 2021-06-18 | 2024-08-15 | Sphingotec Gmbh | A method for predicting sepsis and septic shock |
| WO2023275099A1 (en) | 2021-06-29 | 2023-01-05 | Berysol Gmbh | Composite biomarker for the identification of selenium deficiency in a bodily fluid |
| CN113943374B (zh) * | 2021-09-24 | 2024-04-30 | 广东菲鹏制药股份有限公司 | 一种白介素15及其受体的多肽复合物 |
| CN119072492A (zh) | 2022-03-15 | 2024-12-03 | 艾德里诺医药公司 | 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂 |
| IL318667A (en) | 2022-07-29 | 2025-03-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| US20260028423A1 (en) | 2022-07-29 | 2026-01-29 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| US20260201067A1 (en) | 2022-12-15 | 2026-07-16 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients |
| EP4680966A1 (en) | 2023-03-17 | 2026-01-21 | PAM Theragnostics GmbH | Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose |
| JP2026513177A (ja) | 2023-03-29 | 2026-04-23 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのｄｐｐ３阻害剤 |
| CN121889677A (zh) | 2023-09-25 | 2026-04-17 | 思芬构技术有限公司 | 用于肾移植患者中移植物功能降低的早期诊断、早期预测、监测或严重程度预测的方法 |
| WO2025229075A1 (en) | 2024-05-03 | 2025-11-06 | Sphingotec Gmbh | A method for the specific determination of proenkephalin fragment 119-159 |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
| EP4675277A1 (en) | 2024-07-05 | 2026-01-07 | Predemtec AG | A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease |
| WO2026046968A1 (en) | 2024-08-26 | 2026-03-05 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binders for the treatment of endothelial dysfunction |
| WO2026046978A1 (en) | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| JP3839667B2 (ja) | 1998-06-08 | 2006-11-01 | エフ．ホフマン−ラ ロシュ アーゲー | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7118915B2 (en) | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| AU2003233583A1 (en) | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) * | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| RU2389796C2 (ru) * | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| US7404957B2 (en) | 2003-08-29 | 2008-07-29 | Aerovance, Inc. | Modified IL-4 mutein receptor antagonists |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| EP1996613B1 (en) | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| DE602007009995D1 (de) | 2006-08-01 | 2010-12-02 | Pieris Ag | Muteine von tearlipocalin und verfahren zu deren gewinnung |
| CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| AU2008274938A1 (en) | 2007-07-11 | 2009-01-15 | Aerovance, Inc. | Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation |
| AU2011263786B2 (en) * | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| EP3453400B1 (en) * | 2011-12-13 | 2021-01-20 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
-
2011
- 2011-06-08 AU AU2011263786A patent/AU2011263786B2/en not_active Ceased
- 2011-06-08 HR HRP20190689TT patent/HRP20190689T1/hr unknown
- 2011-06-08 RU RU2012150766/15A patent/RU2569745C2/ru active
- 2011-06-08 SG SG2012089116A patent/SG186161A1/en unknown
- 2011-06-08 TR TR2019/06295T patent/TR201906295T4/tr unknown
- 2011-06-08 DK DK11726380.6T patent/DK2580236T3/da active
- 2011-06-08 CN CN201180028367.9A patent/CN103038249B/zh not_active Expired - Fee Related
- 2011-06-08 PT PT11726380T patent/PT2580236T/pt unknown
- 2011-06-08 LT LTEP11726380.6T patent/LT2580236T/lt unknown
- 2011-06-08 NZ NZ603562A patent/NZ603562A/en not_active IP Right Cessation
- 2011-06-08 SM SM20190297T patent/SMT201900297T1/it unknown
- 2011-06-08 CN CN201610143597.4A patent/CN105949301B/zh not_active Expired - Fee Related
- 2011-06-08 RS RS20190510A patent/RS58839B1/sr unknown
- 2011-06-08 ES ES11726380T patent/ES2729652T3/es active Active
- 2011-06-08 US US13/702,792 patent/US8986951B2/en active Active
- 2011-06-08 JP JP2013513670A patent/JP5902679B2/ja not_active Expired - Fee Related
- 2011-06-08 WO PCT/EP2011/059420 patent/WO2011154420A2/en not_active Ceased
- 2011-06-08 PL PL11726380T patent/PL2580236T3/pl unknown
- 2011-06-08 CN CN202010135181.4A patent/CN111499725A/zh active Pending
- 2011-06-08 HU HUE11726380A patent/HUE043835T2/hu unknown
- 2011-06-08 EP EP11726380.6A patent/EP2580236B1/en active Active
- 2011-06-08 SI SI201131711T patent/SI2580236T1/sl unknown
- 2011-06-08 CA CA2800026A patent/CA2800026C/en active Active
-
2012
- 2012-12-05 ZA ZA2012/09160A patent/ZA201209160B/en unknown
-
2015
- 2015-03-23 US US14/665,692 patent/US9687524B2/en not_active Expired - Fee Related
- 2015-11-06 JP JP2015218174A patent/JP2016028604A/ja active Pending
-
2017
- 2017-06-05 US US15/613,958 patent/US10232014B2/en active Active
-
2019
- 2019-01-24 US US16/256,331 patent/US10898545B2/en not_active Expired - Fee Related
- 2019-01-30 JP JP2019014631A patent/JP6766194B2/ja not_active Expired - Fee Related
- 2019-06-06 CY CY20191100604T patent/CY1122339T1/el unknown
-
2020
- 2020-12-16 US US17/124,141 patent/US20210196788A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201209160B (en) | Tear lipocalin muteins binding il-4 r alpha | |
| IL222361A0 (en) | Lysine specific demethylase-1 inhibitors and their use | |
| IL218778A0 (en) | Lysine specific demethylase - 1 inhibitors and their use | |
| PL2539326T3 (pl) | Połączone bis-arylem arylotriazolony i ich zastosowanie | |
| IL225713A0 (en) | Cytopheric cartridge and its use | |
| GB201013705D0 (en) | Ramp | |
| GB201100578D0 (en) | Lacquer composition and use thereof | |
| AP2013006947A0 (en) | Compounds and their use | |
| HUE041512T2 (hu) | Új kombináció és alkalmazás | |
| GB201006434D0 (en) | Novel iminosugar combinations | |
| GB201014622D0 (en) | Injury prevention kit | |
| GB201013489D0 (en) | Binding surfaces | |
| TWM386576U (en) | Protable hard disc loading device | |
| GB201019908D0 (en) | Ramp pack | |
| TWM400980U (en) | Binding | |
| GB201003979D0 (en) | Handstand blackjack | |
| GB201003839D0 (en) | 3deeko puzzle | |
| GB201006417D0 (en) | Copernisis puzzle | |
| GB201011840D0 (en) | Stacks | |
| PL390444A1 (pl) | Obrotnica i zespół przegubowy | |
| GB201000742D0 (en) | Gp120 binding compounds and their use | |
| GB201001404D0 (en) | Gp120 Binding compounds and their use | |
| HK1184329A (en) | Oligo-benzamide compounds and their use | |
| GB201002337D0 (en) | Compounds and their use | |
| GB201000307D0 (en) | Compounds and their use |